Sigma Planning Corp Cuts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Sigma Planning Corp trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 3.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,627 shares of the company’s stock after selling 1,901 shares during the period. Sigma Planning Corp’s holdings in Hims & Hers Health were worth $1,176,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new stake in Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Venturi Wealth Management LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth approximately $48,000. GAMMA Investing LLC grew its stake in shares of Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the period. Finally, Principal Securities Inc. increased its holdings in shares of Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after purchasing an additional 1,002 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $51.37 on Tuesday. The company has a market cap of $11.22 billion, a price-to-earnings ratio of 116.75 and a beta of 1.35. The stock’s 50-day moving average is $35.45 and its two-hundred day moving average is $26.08. Hims & Hers Health, Inc. has a 1-year low of $9.67 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares in the company, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Michael Chi sold 7,259 shares of the stock in a transaction on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at $4,659,976.07. This trade represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,080,275 shares of company stock worth $37,247,354. Corporate insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on HIMS. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Piper Sandler raised their target price on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Needham & Company LLC raised their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Finally, Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their target price for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.